BioPorto Q2 2020 Interim Report

BioPorto's Q2 2020 interim report covering financial results, NGAL regulatory strategy and status, and the gRAD development platform. The presentation discusses NGAL's relevance during COVID-19 and outlines 2020 milestones for the biotech company.